Neural Noise- ADI Neuroscience, an India-based neurotechnology investment vehicle backed by SPEC Finance India, was announced on August 28, 2026, targeting US$1 billion of investment into India’s neurotechnology sector over five years.1
- The fund is operated by SPEC Finance Group CEO Karan Dinesh Singh Rawat, with scientific advisory from Neiry founder Alexander Panov and Moscow State University professor Mikhail Lebedev, positioning it at the intersection of neurotech entrepreneurship and academic neuroscience.1
- The $1 billion target is roughly two orders of magnitude above the entire prior decade of Indian BCI startup funding combined, marking a step-change in capital availability for the Indian neurotech ecosystem.1
- The announcement moves India onto the same neurotech-capital map as the United States, China, and European alliance-adjacent infrastructure players at a time when BCI is being treated as a strategic technology globally.1
- India does not yet have a domestic regulatory framework specifically for brain-computer interfaces, making both clinical-trial pathways and device approvals contingent on adaptation of existing medical device regulations — a gap the fund’s stated mission of “investment and ecosystem development” would need to help address.1
- The scale of the commitment, if deployed, would position India as a meaningful third geography in the global BCI industry, complementing the US-China duopoly that currently accounts for the majority of disclosed BCI funding.1